The pharmaceutical industry and its lobby groups (eg, Pharmaceutical Research and Manufacturers of America [PhRMA] ) repeat the same traditional arguments to justify high cancer drug prices: 1) high cost of research and development; 2) drug benefit justifies price; 3) market forces drive prices to reasonable levels; and 4) regulating prices stifles innovation. As discussed in previous editorials, 6, 7 all four arguments are implausible. Objective analyses of the cost of research and development place cost at only 10% 6, 14, 15 of the pharmaceutical industry-supported analyses that report figures of $1-2.6 billion (all three studies by the same group) [16] [17] [18] (includes cost of development of drugs that fail during development, ancillary expenses, bonuses, salaries, infrastructures, advertising, etc. . .). Of note, more than half of the important discoveries are made in independent academic and research centers, 19 and funded by taxpayers' money 15, 20, 21 ; and 85% of basic research is conducted in academic centers. 20 The pharmaceutical industry spends 1.3% of its budget on basic research, 22 10% on clinical research, but 20-40% on drug advertisements and related activities. Recently, the drug industry shifted its strategy from in-house research and development, to buying in three-quarters of their pipeline, 23 paying high premiums that increase "cost of research" and consequently drug prices. 23, 24 A pharmaceutical industry CEO stated that the $1 billion cost to develop a drug is "one of the great myths of the industry." 25 Studies show no relationship between drug benefits and price, 26 yet drug companies have established monopoly-like conditions that discourage competition based on price. 27 Finally, innovation is driven primarily by independent investigators who will continue to research and innovate even if drug prices are moderated. 22 High drug prices may in fact divert money out of research and development and prevent the discovery of important cancer drugs. 28 
HARM AS A RESULT OF HIGH CANCER DRUG PRICES
In defending high prices, the drug industry reassures critics that no harm will result from high drug prices and that no patient will go without a needed drug because of mechanisms that offer free drugs to needy patients. In a complex health care system like ours, many patients are unable to navigate the complexities and obstacles required to acquire drugs. Many vulnerable patients, particularly the elderly, the poor and the disadvantaged, may be frustrated and humiliated when faced with these obstacles and decide to abandon care altogether. Medical costs and outof-pocket expenses result in high rates of bankruptcies, 29 and 10%-25% of patients either delay, abandon, or compromise on treatments because of financial constraints. [30] [31] [32] Survival is also compromised. In clinical trials and in countries where tyrosine kinase inhibitors are available to all patients with chronic myeloid leukemia (CML) without financial constraints (eg, Sweden, Germany, Italy), the estimated 8-to 10-year survival in CML is 80%, and the relative survival is similar to a normal population. [33] [34] [35] In contrast, in the United States, where financial considerations may limit access to these agents, the Surveillance, Epidemiology, and End Results (SEER) data show an estimated 5-year survival in CML of 60%. 36 Therefore, there is considerable evidence that high drug prices and out-of-pocket expenses cause delays in therapy or treatment abandonment, that many patients do not have access to charity care or free drugs, and that these conditions harm patients. In surveys, the most significant health care concern of Americans (78%) is the costs of drugs. 37 
HOW ARE CANCER DRUGS PRICED?
The process by which cancer drugs are priced is interesting. According to the pharmaceutical industry, prices are based on objective measures: 1) the cost of research and development, 2) the size of the population at risk, 3) the competitive market in relation to existing drugs and their benefits, and 4) projected profits that would be reasonable to the company. In fact, drug prices may not be based on any of these parameters, but simply on the average price of existing cancer drugs in the market in that year (regardless of tumor indication). Because the price of patented cancer drugs on the market increases at a rate of 8%-12% annually, there is a resulting lockstep increase in the prices of new cancer drugs (10%-20%) at launch. This highlights the importance of the launch price, the price paid by Medicare, which influences all subsequent negotiations between the pharmaceutical industry and insurers, and the price worldwide. Abbreviations: ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer. The interesting exception is cobimetinib ($43,600/year), a drug that is combined with vemurafenib ($78,000/year) to treat melanoma. The combined treatment cost per year is about $122,000.
PROGRESS OVER THE PAST FOUR YEARS
Sadly, 4 years after the issue came to the fore, there has been little if any progress. Cancer drug prices continue to rise relentlessly, compounded by two additional issues: 1) the increasing trend to shift more of the cost of care and cancer drugs to patients [38] [39] [40] and 2) the spill-over of high cancer drug prices to generics. 41 More and more, insurance companies are increasing out-of-pocket expenses for care and drugs. [38] [39] [40] Insurers justify this "skin-in-thegame" strategy as effective in reducing the cost of health care; however, high out-of-pocket expenses have turned this into a "deterrence-in-the-game" strategy that discourages many patients from seeking timely care or purchasing drugs. 38 In a recent survey, one third of insured patients in Texas say they delayed or did not pursue needed care because of high out-of-pocket expenses, 38 and 25%-35% decided either to not buy prescribed drugs or to delay therapy. In addition, the problem of high cancer drug prices has spilled over into the arena of generics, where complex regulatory issues and drug shortages allow pharmaceutical companies to increase the prices of generic drugs to levels as high as those of patented drugs, partly because of the establishment of temporary monopolies. The latest maneuvers by three companies-Turing, Valiant, and Mylan-are only the most extreme examples of a common strategy in pricing drugs. [42] [43] [44] For example, Pfizer increased the price of 133 prescription drugs in 2015, three quarters of them by 10% or more. 45 Another example is the first generic version of imatinib, which was launched in 2016 at a price of $140,000/year (compared with $146,000 for patented imatinib). 46, 47 Generic imatinib is priced at $5000-8000/year in Canada and at $400/ year in India. In this context, the FDA needs to have a critical review of the timelines and cost of filings of drug approvals, particularly for generic drugs. The average cost of filing increased from $1 million in 2003 to $5 million in 2016, and the average time from filing to FDA approval is as long as 4 years (the FDA committed recently to shorten the review time to 15 months). 48 For generic drugs to be priced at true "generic" prices (<30% of the patented drug), 49 at least four to five generic options have to be available. The FDA should develop procedures and guidelines to reduce the cost of filing to less than $1 million per drug, reduce the timeline to approval to 6-12 months, and monitor the availability of multiple generics in the market at all times. There are currently more than 3800 generic drug applications filed with the FDA that are awaiting regulatory action.
The critical discussions regarding high cancer drug prices have heightened public awareness, and high drug prices have become the most important health cancer concern of Americans as well as an important political agenda item. This is even more significant for senior citizens, who are least able to afford high out-of-pocket expenses-particularly for cancer drugs, which often are more in demand among older Americans, who are more prone to develop cancers.
Despite expressing a desire to be part of the solution, the pharmaceutical industry has done little to address the problem-perhaps hoping that apathy might settle in or that this concern will be displaced by more urgent ones, thus allowing additional years of excessive profits. In 2016, with mounting pressure from patients and advocates, the pharmaceutical industry initiated a concerted campaign costing more than $100 million to counter the negative publicity with advertisements and other related activities. 50 This public relations campaign follows the playbook fundamentals or spin that businesses often use in such instances and is detailed in an outstanding book, Deadly Spin, by Wendell Potter, a previous vice president of public relations at CIGNA. 51 These activities to promote the pharmaceutical industry viewpoints include: hiring large, well-connected public relation firms and lobbying groups (including PhRMA); setting up and funding coalitions and groups with lofty titles that include buzzwords such as "American," "freedom," "choice," "public," etc.; writing letters to the editors and op-ed pieces in local and national publications; advertising in news media the importance of the pharmaceutical industry in solving medical problems (as in a recent advertisement by several drug companies); feeding talking points and carrying out duplicitous communication campaigns (eg, claiming to be part of the solution); and influencing the tone and content of published articles to favor the drug company opinions regarding high cancer drug prices. 51 This is illustrated in recent drug company-sponsored research that reported good "treatment values" for drugs used in hematologic malignancies 52 but that were contradicted by independent research. 53, 54 A recent analysis directed at the pharmaceutical industry groups reminded its readers that the industry reputation is worse today than that of airlines and banks; that anyone who continues to use cost of innovation to defend price must be ready to disclose the dollars invested; and that the days of unchallenged pricing are coming to an end. 55 The analysis detailed strategies that should be pursued in 2017, proposing several new talking points, including: 1) high cancer drug prices are needed to support future (not past) research and development cost; 2) the need to "do a better job" in defining value; 3) the message Editorial must be rooted in the old saying that "value is in the eye of the beholder"; 4) the need for "new intensely human ways to show who we are"; and 5) "companies must gently remind . . . the race for cures for cancer, Alzheimer's and Parkinson's." 55 Unfortunately, none of the public relation strategies or "being part of the solution" addresses lowering the exorbitant cancer drug prices. Of interest, some drug industry CEOs favor lowering cancer drug prices, as we have done in previous editorials, 7 arguing that affordable drugs will have deeper market penetration, keeping more patients alive who continue to purchase and use these drugs, and therefore generating more long-term profits. 56 
ROLE OF PATIENT ADVOCACY GROUPS
Several societies and organizations represent oncologists, their associates, and patients with cancer: the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research, the American Society of Hematology, the American Cancer Society, the Leukemia & Lymphoma Society (LLS), and others, as well as patient groups and organizations. Except for ASCO, all other official cancer societies have remained quite silent. The position of the LLS is of particular interest. A recent article in The New York Times highlights its close collaboration with the drug industry. The article points out that LLS has frequently criticized insurers for exposing patients to high out-of-pocket expenses and has commissioned studies to look at the impact of this issue, but has not spoken about the drug industry strategies to set high cancer drug prices. The article also points out that eight of the LLS's 16 largest donors are drug companies, each having donated more than $1 million 2015, and that the LLS actively solicited corporate sponsorships on its website, pointing to the LLS's "powerful footprint of millions of constituents" and describing the society as "an outstanding cause to build good will, positive public relations and marketing benefits that align with your brand and reputation." 57 These statements have been removed from the LLS website since the article appeared. 57 It is perhaps time, 4 years later, for patient advocacy organizations to shed their worries about existing relationships with the powerful pharmaceutical industry and engage in positive discussions and solutions to make drugs available and affordable to all Americans with cancer.
SOLUTIONS
Several immediate and significant solutions can be implemented to reduce the cost of cancer drugs; these have been detailed by multiple cancer experts, [7] [8] [9] [10] [11] health care economists, elected representatives, and presidential candidates and include the following:
1. Allow Medicare to negotiate cancer drug prices. It is estimated this would have saved $400-800 billion over a decade. 58 2. Establish a post-FDA mechanism to review the benefits of recently approved drugs and to define a fair price. This is of critical importance, because the initial launch price in the United States influences the prices in all subsequent negotiations between drug companies and insurers as well as with foreign governments. 3. Encourage cancer societies and organizations to incorporate the price of cancer drugs into definitions of "treatment value" and therapeutic algorithms. 4. Allow patients to import cancer drugs across borders. 9 5. Prevent strategies that delay the availability of generic drugs. This saved the US health care system $227 billion in 2015 and about $1.46 trillion over a decade. 59 6. Review the FDA drug approval costs and timelines. 7. Request that drug companies report transparently the costs of research and development to justify the proposed cancer drug prices.
Unfortunately, these obvious measures appear to be opposed in Congress by our elected representatives (perhaps because of the influence of the drug industry lobby, the most powerful one in the United States), who seem to represent the industry interests rather than the interest of the American citizens who elected them. Future actions and legislations will reveal whether the United States is the democracy we believe it is, or whether it has been gradually transformed into a "pharmaceutocracy."
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